A new study validates a simple prognostic score, the EUTOS score, as a useful tool in predicting the therapeutic effects of TKIs for chronic myeloid leukemia.
ARIAD has received marketing authorization from the European Commission for ponatinib (Iclusig) in chronic myeloid leukemia and acute lymphoblastic leukemia.
The American Society of Clinical Oncology (ASCO) has updated its guidelines on treating women at high risk of developing breast cancer with pharmacologic drugs.
A study including 17 cohorts with a total of more than 300,000 individuals found that ambient air pollution of various types contributes to lung cancer incidence across nine European countries.
Last week, the FDA announced that it would grant priority review to pertuzumab (Perjeta), as a neoadjuvant treatment for women with HER2-positive early-stage breast cancer.
A randomized, phase II trial showed improved progression-free survival in small-cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the ASCO annual meeting in Chicago.
Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India.
Women diagnosed with estrogen-receptor (ER)-positive breast cancer who took tamoxifen for 10 years as adjuvant therapy had lower risk of late recurrence and lower risk of death compared to those who took the drug for 5 years. These results corroborate the findings of the international ATLAS trial.
Limited surgical resection of duodenal gastrointestinal stromal tumors resulted in positive outcomes for both local and systemic disease-free survival, according to the results of a small study.
The US Food and Drug Administration approved the multi-kinase inhibitor regorafenib (Stivarga) yesterday, for the treatment of patients with unresectable metastatic gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib.